SCHEMBL5372576

SCHEMBL5372576

O=C1c2ccccc2C(=O)N1Sc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CES2 O00748 1/20 0.40
BCHE P06276 1/20 0.40
CES1 P23141 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
MC4R P32245 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
AR P10275 1/20 0.39
ALPL P05186 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL809458 0.84 CASP3 (0.48) MAPTRAB9AALDH1A1HSD17B10PKM
SCHEMBL30872008 0.84 CASP3 (0.48) MAPTRAB9AALDH1A1HSD17B10PKM
SCHEMBL11105056 0.82 KMT2A (0.46) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL20503165 0.82 MEN1 (0.52) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL28673975 0.81 GSK3B (0.44) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL29727795 0.81 MAP2K7 (0.41) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL29727850 0.80 MMP2 (0.43) MEN1KMT2AMAPTALDH1A1HSD17B10
SCHEMBL16694595 0.77 RAB9A (0.50) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL29475759 0.77 RAB9A (0.50) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL11450996 0.73 MEN1 (0.40) MEN1KMT2AMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US claimed
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2023-06-22 US claimed
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US disclosed
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2023-06-22 US disclosed
US-11548910-B2 Oligonucleotide production method NISSAN CHEMICAL CORPORATION (JP) 2023-01-10 US disclosed
CN-110330526-B Green synthesis method of thiophosphite 成都理工大学 2021-11-26 CN disclosed
CN-110330526-A A kind of green synthesis method of thio phosphinate 成都理工大学 2019-10-15 CN disclosed
US-20190169223-A1 OLIGONUCLEOTIDE PRODUCTION METHOD NISSAN CHEMICAL CORPORATION (JP) 2019-06-06 US disclosed
EP-3378869-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Nissan Chemical Corporation (JP) 2018-09-26 EP disclosed
CN-103936805-B A kind of nucleotide and/or oligonucleotide and preparation method thereof 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 2016-12-28 CN disclosed
CN-103936805-A Nucleotide and/or oligonucleotide and preparation method thereof KUNSHAN INDUSTRY TECHNOLOGY RES INST SMALL NUCLEIC ACID BIOLOG TECHNOLOGY INST CO LTD 2014-07-23 CN disclosed
EP-1325927-A2 Synthesis of oligonucleotides Avecia Limited (GB) 2003-07-09 EP disclosed
US-20030083490-A1 Solution phase synthesis of oligonucleotides AVECIA LIMITED 2003-05-01 US disclosed
EP-1003758-B1 SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AVECIA LTD (GB) 2003-04-09 EP disclosed
US-6506894-B1 Phosphonation; oxidation in situ with sulfur transfer agent AVECIA LIMITED (GB) 2003-01-14 US disclosed
US-5879872-A ANTIFOGGANTS EASTMAN KODAK COMPANY (US) 1999-03-09 US disclosed
EP-0004320-B1 1-SUBSTITUTED-THIOMETHYLTRIAZOLOBENZODIAZEPINES, PREPARATION THEREOF, THEIR USE, AND A PHARMACEUTICAL COMPOSITION SHIONOGI & CO., LTD. (JP) 1981-12-16 EP disclosed
US-4264499-A PSYCHOTROPIC AGENTS, ANXIOLYTICS, ANTICONVULSANTS, HYOTICS SHIONOGI & CO., LTD. (JP) 1981-04-28 US disclosed
US-4231930-A PSYCHOTROPIC AGENTS, ANXIOLYTICS, ANTICONVULSANTS, HYPNOTICS SHIONOGI & CO., LTD. (JP) 1980-11-04 US disclosed
EP-0004320-A1 1-Substituted-thiomethyltriazolobenzodiazepines, preparation thereof, their use, and a pharmaceutical composition SHIONOGI & CO., LTD. (JP) 1979-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083490-A1 Solution phase synthesis of oligonucleotides NUDT1, POLR2E, POLRMT MEN1 2369/4885KMT2A 3491/4885MAPT 1792/4885
US-11548910-B2 Oligonucleotide production method RNGTT, OSGEP, PHAX MEN1 3165/4885KMT2A 2395/4885MAPT 3183/4885
US-20190169223-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, OSGEP, PHAX MEN1 3165/4885KMT2A 2395/4885MAPT 3183/4885
US-12492220-B2 Method for the preparation of oligonucleotides POLN, POLRMT, POLI MEN1 3413/4885KMT2A 3340/4885MAPT 3637/4885
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES POLN, POLRMT, POLI MEN1 3413/4885KMT2A 3340/4885MAPT 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.